AR068539A1 - Formulaciones galenicas de compuestos organicos - Google Patents
Formulaciones galenicas de compuestos organicosInfo
- Publication number
- AR068539A1 AR068539A1 ARP080104136A ARP080104136A AR068539A1 AR 068539 A1 AR068539 A1 AR 068539A1 AR P080104136 A ARP080104136 A AR P080104136A AR P080104136 A ARP080104136 A AR P080104136A AR 068539 A1 AR068539 A1 AR 068539A1
- Authority
- AR
- Argentina
- Prior art keywords
- dosage form
- oral dosage
- solid oral
- heart failure
- organic compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se refiere a una forma de dosificacion oral solida compactada con rodillo que comprende una cantidad terapéuticamente efectiva de alisquireno, o una sal farmacéuticamente aceptable del mismo, en donde el ingrediente activo está presente en una cantidad mayor del 38 por ciento en peso, con base en el peso total de la forma de dosificacion oral, así como a un proceso para preparar la forma de dosificacion oral solida. Reivindicacion 12: Una forma de dosificacion oral solida de acuerdo con cualquiera de las reivindicaciones anteriores, para el tratamiento de hipertension, insuficiencia cardiaca congestiva, angina, infarto de miocardio, arterioesclerosis, nefropatía diabética, miopatía cardíaca diabética, insuficiencia renal, enfermedad vascular periférica, hipertrofia de ventrículo izquierdo, disfuncion cognitiva, embolia, dolor de cabeza, e insuficiencia cardiaca cronica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97589407P | 2007-09-28 | 2007-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068539A1 true AR068539A1 (es) | 2009-11-18 |
Family
ID=40377181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104136A AR068539A1 (es) | 2007-09-28 | 2008-09-24 | Formulaciones galenicas de compuestos organicos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20110033533A1 (es) |
| EP (2) | EP2548553A1 (es) |
| JP (1) | JP5378384B2 (es) |
| KR (1) | KR20100076996A (es) |
| CN (1) | CN101808630A (es) |
| AR (1) | AR068539A1 (es) |
| AU (1) | AU2008303504C1 (es) |
| BR (1) | BRPI0817586A2 (es) |
| CA (1) | CA2697229A1 (es) |
| CL (1) | CL2008002828A1 (es) |
| CO (1) | CO6270216A2 (es) |
| GT (1) | GT201000064A (es) |
| MA (1) | MA31768B1 (es) |
| MX (1) | MX2010003260A (es) |
| MY (1) | MY148266A (es) |
| NZ (1) | NZ584005A (es) |
| PE (1) | PE20091203A1 (es) |
| RU (1) | RU2483718C2 (es) |
| TN (1) | TN2010000120A1 (es) |
| TW (1) | TWI436760B (es) |
| WO (1) | WO2009040373A2 (es) |
| ZA (1) | ZA201001144B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102036948A (zh) * | 2008-05-23 | 2011-04-27 | 特瓦制药工业有限公司 | 阿利吉仑单富马酸盐及其制备方法 |
| WO2011116115A1 (en) | 2010-03-16 | 2011-09-22 | Novartis Ag | Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing |
| TR201002256A1 (tr) * | 2010-03-24 | 2011-10-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Stabil aliskiren formülasyonları |
| US20110268797A1 (en) | 2010-04-30 | 2011-11-03 | Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi | Multicoated aliskiren formulations |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| US6521647B2 (en) * | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
| CA2430924A1 (en) * | 2000-12-01 | 2002-06-06 | Novartis Ag | Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition |
| RU2183116C1 (ru) * | 2001-07-10 | 2002-06-10 | Жаров Олег Владимирович | Фармацевтическая композиция, обладающая болеутоляющим, противовоспалительным, антипиретическим и спазмолитическим действием |
| US20040266743A1 (en) * | 2003-05-09 | 2004-12-30 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and a renin inhibitor |
| AR048431A1 (es) * | 2004-03-17 | 2006-04-26 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| US20050220865A1 (en) * | 2004-04-02 | 2005-10-06 | Koleng John J | Compressed composition comprising magnesium salt |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| CA2605771A1 (en) * | 2005-04-27 | 2006-11-02 | Novartis Ag | Methods of treating atherosclerosis |
| RU2008122712A (ru) * | 2005-11-08 | 2009-12-20 | Новартис АГ (CH) | Комбинация органических соединений |
| TW200804241A (en) * | 2006-02-24 | 2008-01-16 | Novartis Ag | New salt |
| GB0605688D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
| EP1891937A1 (en) * | 2006-08-25 | 2008-02-27 | Novartis AG | Galenic formulations of aliskiren |
| JP2010509254A (ja) * | 2006-11-09 | 2010-03-25 | ノバルティス アーゲー | アリスキレンとオロチン酸の塩 |
| EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
| WO2009045795A2 (en) * | 2007-09-28 | 2009-04-09 | Novartis Ag | Galenical formulations of aliskiren and valsartan |
-
2008
- 2008-09-24 EP EP12188621A patent/EP2548553A1/en not_active Withdrawn
- 2008-09-24 US US12/679,088 patent/US20110033533A1/en not_active Abandoned
- 2008-09-24 KR KR1020107009195A patent/KR20100076996A/ko not_active Ceased
- 2008-09-24 WO PCT/EP2008/062769 patent/WO2009040373A2/en not_active Ceased
- 2008-09-24 RU RU2010116530/15A patent/RU2483718C2/ru not_active IP Right Cessation
- 2008-09-24 MX MX2010003260A patent/MX2010003260A/es active IP Right Grant
- 2008-09-24 CN CN200880108854A patent/CN101808630A/zh active Pending
- 2008-09-24 AU AU2008303504A patent/AU2008303504C1/en not_active Ceased
- 2008-09-24 PE PE2008001663A patent/PE20091203A1/es not_active Application Discontinuation
- 2008-09-24 AR ARP080104136A patent/AR068539A1/es unknown
- 2008-09-24 CL CL2008002828A patent/CL2008002828A1/es unknown
- 2008-09-24 EP EP08804674A patent/EP2205232A2/en not_active Withdrawn
- 2008-09-24 BR BRPI0817586 patent/BRPI0817586A2/pt not_active IP Right Cessation
- 2008-09-24 TW TW097136655A patent/TWI436760B/zh not_active IP Right Cessation
- 2008-09-24 MY MYPI2010000722A patent/MY148266A/en unknown
- 2008-09-24 CA CA2697229A patent/CA2697229A1/en not_active Abandoned
- 2008-09-24 JP JP2010526278A patent/JP5378384B2/ja not_active Expired - Fee Related
- 2008-09-24 NZ NZ584005A patent/NZ584005A/xx not_active IP Right Cessation
-
2010
- 2010-02-17 ZA ZA2010/01144A patent/ZA201001144B/en unknown
- 2010-03-17 GT GT201000064A patent/GT201000064A/es unknown
- 2010-03-19 TN TNP2010000120A patent/TN2010000120A1/fr unknown
- 2010-04-08 MA MA32758A patent/MA31768B1/fr unknown
- 2010-04-19 CO CO10045478A patent/CO6270216A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20091203A1 (es) | 2009-09-11 |
| CL2008002828A1 (es) | 2009-05-15 |
| BRPI0817586A2 (pt) | 2015-03-31 |
| NZ584005A (en) | 2012-08-31 |
| WO2009040373A2 (en) | 2009-04-02 |
| MX2010003260A (es) | 2010-04-29 |
| US20110033533A1 (en) | 2011-02-10 |
| WO2009040373A3 (en) | 2009-08-20 |
| KR20100076996A (ko) | 2010-07-06 |
| TN2010000120A1 (en) | 2011-09-26 |
| ZA201001144B (en) | 2011-12-28 |
| JP2010540489A (ja) | 2010-12-24 |
| JP5378384B2 (ja) | 2013-12-25 |
| EP2548553A1 (en) | 2013-01-23 |
| CA2697229A1 (en) | 2009-04-02 |
| CN101808630A (zh) | 2010-08-18 |
| GT201000064A (es) | 2012-03-30 |
| EP2205232A2 (en) | 2010-07-14 |
| RU2483718C2 (ru) | 2013-06-10 |
| MA31768B1 (fr) | 2010-10-01 |
| TWI436760B (zh) | 2014-05-11 |
| AU2008303504C1 (en) | 2013-05-16 |
| AU2008303504A1 (en) | 2009-04-02 |
| RU2010116530A (ru) | 2011-11-10 |
| TW200922546A (en) | 2009-06-01 |
| CO6270216A2 (es) | 2011-04-20 |
| MY148266A (en) | 2013-03-29 |
| AU2008303504B2 (en) | 2012-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066168A1 (es) | Formulaciones galenicas de compuestos organicos | |
| MX2022015026A (es) | Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo. | |
| GT201200164A (es) | "nuevos compuestos de espiropiperidina" | |
| CL2011001848A1 (es) | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. | |
| AR075179A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno | |
| AR124688A2 (es) | Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo | |
| CO6382125A2 (es) | Inhibidores de proteína quinasa | |
| CO6470847A2 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| AR070731A1 (es) | Composicion farmaceutica para farmacos poco solubles | |
| CO6531458A2 (es) | Nuevos compuestos de espiropiperidina | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| PE20190405A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4beta7 | |
| ECSP066807A (es) | Formulaciones galénicas de compuestos orgánicos | |
| UY32660A (es) | Derivados aminobutricos sustituidos como inhibidores de neprilisina | |
| DOP2006000170A (es) | Nuevos derivados de espirocromanona | |
| AR047993A1 (es) | Composicion farmaceutica que comprende pimobendano | |
| ECSP10010428A (es) | Derivados de indazol | |
| CL2010000059A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-diflurobenzamida o una sal farmaceuticamente aceptable; forma polimorfica de la sal clorhidrato; composicion farmaceutica; y su uso para tratar una enfermedad del sistema nervioso central tal como dolor, sindrome metabolico, inflamacion, alzheimer. | |
| AR068539A1 (es) | Formulaciones galenicas de compuestos organicos | |
| PA8629501A1 (es) | Tabletas dispersables que comprenden un derivado de acido benzoico | |
| AR073651A1 (es) | Formulaciones galenicas de compuestos organicos | |
| UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
| AR085942A1 (es) | Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio | |
| EA201200754A1 (ru) | Традиционное китайское лекарственное средство, содержащее экстракты дан-шен (danshen) и сан-ки (sanqi), и его применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |